A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Clinical trial NCT04155580 · TERMINATED
Trial details
- NCT number
- NCT04155580
- Sponsor
- Astex Pharmaceuticals, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-12
- Primary completion
- 2022-01-14
- Enrollment
- 68
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.